Laws to control drugs have been progressively introduced since the early twentieth century to reduce non-medical use and drug-associated harm. Restrictions on what are now deemed ‘controlled drugs’ and, in New Zealand, ‘prohibited plants’ unjustly impact both medical care and research. The impact on research has frequently been cited in reference to the use ...
Nicotine dependence remains a leading cause of preventable mortality worldwide. Pharmacotherapy and behavioral interventions offer modest efficacy with limited long-term success. Psilocybin-assisted psychotherapy (PAP) is an emerging approach to nicotine cessation with a growing evidence base. As PAP research expands, understanding how nicotine users’ attitu...
Background: Tramadol is a synthetic opioid analgesic prescribed for moderate pain. Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a naturally occurring psychoactive compound found in certain mushrooms, often referred to as "magic mushrooms" and is classified as a Schedule I substance. This case report aimed to present the unexpected detection of psil...
Introduction Psychedelic Assisted Psychotherapy (PAP) has been legal in Switzerland since 2014 under supervised exceptional medical use with MDMA, LSD and Psilocybin with case by case authorisations delivered from the Federal Office of Public Health. In particular, since 2021, we have implemented a clinical activity at Geneva University Hospital (HUG) for tr...
Introduction Mental health disorders, including depression, anxiety, and post-traumatic stress disorder (PTSD), remain a significant global health concern, requiring novel therapeutic approaches. Psilocybin, a psychedelic compound found in certain mushrooms, has shown potential in modulating neuroplasticity, a critical process for cognitive flexibility and m...
Amid an evolving psychedelic drug policy landscape and limitations of existing substance use disorder (SUD) treatments, a novel addiction recovery paradigm has emerged involving augmentation of 12-Step program engagement with therapeutic psychedelic use. A preliminary qualitative analysis was initiated to describe this movement by examining real-world experi...
The emergence of microdosing introduced a novel approach to consuming classic psychedelic substances, such as LSD (lysergic acid diethylamide) and psilocybin mushrooms, in ways previously unconventional. Whereas traditional illicit substance use often seeks euphoric experiences, microdosing deliberately avoids such effects in favor of perceived self-enhancin...
Abstract Background Psychedelic and dissociative drugs, including psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), and ketamine, have garnered significant interest for their therapeutic potential in treating various mental health disorders. However, their psychoactive properties pose substantial risks when used in conte...
Psychedelics are undergoing a clinical research renaissance, with compounds such as psilocybin advancing to Phase 3 trials for treatment-resistant depression and receiving fast-track or breakthrough designations from regulatory agencies. Despite this progress, the field lacks standardized terminology to guide clinical development, dosing, safety monitoring, ...
Established by the 1971 United Nations (UN) Convention on Psychotropic Substances, the prohibition of the recreational use of psychedelics (lysergic acid diethylamide [LSD], psilocybin, N, N -dimethyltryptamine [ N, N -DMT], and mescaline) has two premises. First, recreational use poses a serious threat to public health because psychedelics are highly liable...
Interest in and use of hallucinogens appears to be growing in the United States, yet less is known about the use of multiple hallucinogens. The aims of this study are to characterize subgroups of lifetime hallucinogen use and to identify sociodemographic correlates of these subgroups. Latent class models were fit using 2021-2022 National Survey on Drug Use a...
Psychedelic-assisted therapies and ketamine are two modalities gaining attention in psychiatry for treating conditions such as depression, PTSD, and substance use disorders. However, perceptions of these treatments vary globally. This study explores the familiarity, attitudes, and perceptions of Jordanian physicians and medical students toward psychedelic su...
Psychedelic-assisted psychotherapy (PAP) constitutes a novel treatment paradigm in mental health care practice that is currently being evaluated for its clinical efficacy and safety. Insight into the attitudes of clinicians toward PAP remains crucial for its successful integration into mental health care. This cross-sectional survey explores the attitudes of...
This study examined patient perspectives on psilocybin therapy, specifically their acceptance and views on the therapeutic benefits of both hallucinogenic and non-hallucinogenic forms. A cross-sectional survey was conducted among psychiatric patients aged 18-65 at a community mental health center, assessing their attitudes, knowledge, and acceptance of psilo...
4-Phosporyloxy-N, N-dimethyltryptamine (psilocybin) is a psychedelic tryptamine found in certain mushroom species that has shown efficacy in the treatment of various psychiatric disorders. In conjunction with the renewed interest in therapeutic effects of psychedelics, there has been an increase in psilocybin-like designer tryptamines appearing in non-medica...
Motives are a highly influential force in substance use and vary depending on the substance or dose being used. Little research has compared motives across different doses of psilocybin. Psilocybin is often ingested in microdoses (0.1-0.4 g) or macrodoses (1 g+), each producing unique perceptual and mood effects. The current study examined whether motives fo...
Although there is growing support for the protective effects of psychedelics on mental health, recent evidence finds racial and ethnic minorities gain fewer benefits. This paper aims to test whether the disparate mental health outcomes associated with psychedelic use extend across multiple racial and ethnic groups, including non-Hispanic Whites, Blacks, Asia...
